Belgium· BE-AMP-SAM593786-00
Cibinqo 100 mg
A abrocitinib product containing abrocitinib, registered in Belgium by Pfizer Europe MA. The same ATC class is registered in 15 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Abrocitinib is registered in 15 of 19 countries.
Countries holding a registration under ATC D11AH08 (abrocitinib), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Abrocitinib · ATC D11AH08
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of abrocitinib costs, country by country.
Normalised to the WHO defined daily dose (0.15 g), the median price runs from $0.26 in France to $295.64 in United States — a ×1143 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Abrocitinib · price per daily dose (0.15 g)
USD · FX 28 Sept 2026
- US United States$295.64 (acquisition cost)
- CH Switzerland$122.11
- FR France$0.26
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Abrocitinib
- Manufacturer
- Pfizer Europe MA
- Country
- Belgium (BE)
- ATC code
- D11AH08
- ATC class
- Abrocitinib
- Defined daily dose
- 0.15 g, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 3
2 priced- be_apb4405395EUR 1324.25
- be_apb4405429EUR 3466.9
- be_apb7737653
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Abrocitinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesCibinqoPfizer Laboratories Div Pfizer Inc
- CzechiaCIBINQOPfizer Europe MA EEIG, Bruxelles
- SwitzerlandCibinqo
- FinlandCibinqoPfizer Europe MA EEIG
- FranceCIBINQO 100 mg, comprimé pelliculéPFIZER EUROPE MA EEIG (BELGIQUE)
- IrelandCibinqo 100 mg film-coated tabletsPfizer Europe MA EEIG
- IcelandCibinqoPfizer Europe MA EEIG*
- NetherlandsCibinqo 100 mg, filmomhulde tablettenPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Cibinqo
- Liechtenstein · Cibinqo
- Norway · Cibinqo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2650da0b-65dd-443a-91fc-efafe9892274 GET /v1/drugs/2650da0b-65dd-443a-91fc-efafe9892274?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Cibinqo 100 mg",
"name_fr": "Cibinqo 100 mg",
"name_nl": "Cibinqo 100 mg",
"amp_code": "SAM593786-00",
"strengths": [
"100.0000",
"2.7300"
],
"pack_count": 5,
"substances": [
"Abrocitinib",
"Lactose Monohydrate",
"Sodium Starch Glycolate"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Abrocitinib",
"authorisation_numbers": [
"EU/1/21/1593/008",
"EU/1/21/1593/009",
"EU/1/21/1593/006",
"EU/1/21/1593/007",
"EU/1/21/1593/010"
]
}See everything about abrocitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.